Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.
Optune® Novocure™

The Optune® system

Smaller. Lighter. Designed for everyday life. 3 more reasons to recommend Optune for appropriate patients.

Novocure™ is pleased to introduce the second generation Optune System. It is smaller and lighter, weighing just 2.7 lbs.

Optune® Components

Optune components

The complete system includes a portable electric field generator, transducer arrays, rechargeable batteries, and more.
Optune® electric field generator

Electric field generator

The portable field generator can be carried with you to generate Tumor Treating Fields (TTFields) as you go about your day.
Optune® transducer array

Transducer array

Sterile, single-use transducer arrays are connected to the electric field generator to deliver therapy. Transducer arrays should be changed at least 2 times per week (every 4 days at most).
Optune® connection cable and box

Connection cable and box

Black and white coded sockets on the cable box help ensure that transducer arrays are properly connected.
Optune® easy-access sleeve bag

Easy access sleeve bag

Openings conveniently located at the top and bottom make it easy to reach device controls

Convertible, 5-in-1 bag

This bag can be worn 5 different ways and has additional battery storage, making it ideal for on-the-go use.

The second generation Optune System is designed for enhanced carrying comfort and usability:

  • Easy-grip texture allows for better handling

  • Battery indicator displays power and alerts patients when it’s time to change the battery

  • Light-detecting sensor auto-dims the device and the charger in the dark

Other components include:

  • Portable batteries: 4 batteries are provided with each kit; each battery lasts for 2 to 3 hours

  • Charger for portable batteries: Batteries will need to be recharged for 2 to 4 hours. The batteries can be charged and used many times for about 6 to 9 months

  • Plug-in power supply and power cords: New “No-Stop Swap” enables patients to swap batteries or power source without disrupting delivery of TTFields

Review the results

Learn more about the efficacy results in newly diagnosed GBM.

See the data

How Optune works

See how Tumor Treating Fields (TTFields) disrupt mitosis and inhibit tumor growth.

Watch video


*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information


Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).